SIRION Biotech is a company specializing in viral vectors for gene therapy and vaccine applications. Viral vectors are a perfect method for genetically modifying human or animal cells for ‘healthier’ performance overall.

While gene therapy is still in its infancy and expected to grow significantly, vaccine applications are a $ 30 billion market, continuing to grow at a double digit rate. Many more lives will be saved once gene therapy and novel prime boost vaccines arrive on the markets.

The company's unique BAC-technology (Bacterial Artificial Chormosomes) allows SIRION Biotech to build viral vectors from scratch according to specified development needs. BAC-technology (AdenoONE™) has substantial advantages over current industry standards in that it generates 100% positive and stable clones and allows for entire expression libraries. The company's expertise realizes gene knockdowns of nearly 100%, while the industry standard is around 50-70%.

This removes uncertainty from research results. Cell models for new drugs or for food and cosmetic ingredients are available in just 6 weeks, substantially faster than with traditional methods.